this proposal does not extend to such platforms and applications in part because other than some DTx, few have evidence demonstrating improved behavioral health outcomes
Medicare Part D claims data for CY 2023 indicates there were 2,662 prescriptions filled that year for compounded immunosuppressive drugs that could have been administered through oral or enteral routes (that is, that would likely be paid under Part B if the immunosuppressive drug benefit revision is finalized as proposed)
If finalized, CMS would apply the policies described above to rebate calculations beginning with the applicable period that began on October 1, 2022
In sections IV.A.4.e (4)(e)(iii) of this proposed rule, we note that we recently released the CMS Interoperability and Prior Authorization final rule which appeared in the Federal Register on February 8, 2024 (89 FR 8758)
The weekly and monthly formulations of Brixadi are described by HCPCS codes J0577 ( Injection, buprenorphine extended release (brixadi), less than or equal to 7 days of therapy ) and J0578 ( Injection, buprenorphine extended release (brixadi), greater than 7 days and up to 28 days of therapy )
By adding the new studies to the list of studies selected in our first estimates and revising the meta-analyses, we found that the pooled estimates were statistically significant for cancers of the mouth (Fig
